Glycerol Suppositories
Brand names: Glycerin Suppositories BP
Glycerol (glycerin) suppositories are a rectally administered osmotic and lubricant laxative used for the short-term relief of constipation.
Adult dose
Dose adjustments
Not stated in the retrieved sections.
Not stated in the retrieved sections.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Known hypersensitivity to glycerol
- Adult-size suppositories are not suitable for use by children and infants (§4.3)
- Not to be swallowed — suppositories must not be taken by mouth (§4.4)
Side effects
- Gastrointestinal disorders: may cause irritation and occasionally abdominal cramps (§4.8, the whole adverse-effect statement)
Interactions
- None known (§4.5)
Clinical monograph
How it works
Inserted into the rectum, glycerol acts osmotically to draw water into the bowel and has a mild local irritant and lubricant effect that stimulates rectal evacuation.
Prescribing in practice
- They are for occasional, short-term use only and should not be relied upon long term, as the underlying cause of constipation should be addressed.
- Moistening the suppository before insertion improves comfort, and onset of action is usually rapid.
- Avoid in patients with bowel obstruction or undiagnosed rectal bleeding until assessed.
Monitoring
No routine laboratory monitoring is needed; assess the clinical response and review if constipation persists or recurs.
Counselling the patient
- Moisten the suppository with water before gently inserting it into the back passage and try to retain it for a short while.
- Expect the medicine to work fairly quickly; seek advice if there is no result or if you have persistent bleeding.
Evidence & guidelines
Rectal glycerol is a long-established, widely used measure for the short-term relief of constipation.
Reference: NICE NG128 Constipation; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021